Seres Therapeutics (NASDAQ:MCRB - Get Free Report) is scheduled to be posting its quarterly earnings results before the market opens on Wednesday, May 8th. Analysts expect Seres Therapeutics to post earnings of ($0.36) per share for the quarter. Parties that wish to register for the company's conference call can do so using this link.
Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last announced its earnings results on Tuesday, March 5th. The biotechnology company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.08. The firm had revenue of $0.06 million during the quarter, compared to the consensus estimate of $0.50 million. On average, analysts expect Seres Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Seres Therapeutics Stock Performance
Shares of NASDAQ:MCRB traded down $0.08 during midday trading on Tuesday, hitting $1.11. The company's stock had a trading volume of 6,549,646 shares, compared to its average volume of 4,818,297. Seres Therapeutics has a fifty-two week low of $0.54 and a fifty-two week high of $6.26. The stock has a market capitalization of $167.62 million, a price-to-earnings ratio of -1.23 and a beta of 2.16. The stock's 50 day simple moving average is $0.84 and its 200 day simple moving average is $1.06.
Wall Street Analyst Weigh In
Several research analysts have commented on MCRB shares. Chardan Capital dropped their price target on Seres Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a research report on Wednesday, March 6th. Oppenheimer cut their target price on shares of Seres Therapeutics from $9.00 to $5.00 and set an "outperform" rating for the company in a research note on Wednesday, March 6th.
Check Out Our Latest Analysis on Seres Therapeutics
About Seres Therapeutics
(
Get Free Report)
Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.
Featured Articles
Before you consider Seres Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Seres Therapeutics wasn't on the list.
While Seres Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
